Arrythmia Burden in Cardiac Contractility Modulation (CCM)
- Conditions
- Atrial FibrillationArrythmia
- Interventions
- Device: Impulse Dynamics Optimizer Device
- Registration Number
- NCT05704426
- Lead Sponsor
- Hackensack Meridian Health
- Brief Summary
The Impulse Dynamics Optimizer Device is a Food and Drug Administration (FDA) approved; commercially available device indicated for patients with heart failure with reduced ejection fraction (HFrEF). Many candidates of this device have a previously implanted cardiovascular implantable electronic device (CIED)- internal cardioverter defibrillator (ICD) or permanent pacemaker (PM). Patients with heart failure are at high risk for both atrial and ventricular cardiac arrhythmias.
The aim of this study is to evaluate patients for Atrial fibrillation (AF) burden episode data obtained from interrogation of their CIED 8 months or greater after Optimizer implant and compare arrhythmia burden 6 months before Optimizer Cardiac Contractility Modulation (CCM) device insertion to 8 months or greater after Optimizer insertion (after 2 month blanking period).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 2
- 1%≤AF burden≤99% in the 6 month period prior to Optimizer implant as documented the patient's CIED
- 18 years of age or older on day of signing consent
- Any gender
- Functional pacemaker or ICD and using remote follow-up for their CEID
- Not scheduled for planned catheter ablation or cardioversion
- Ability to sign consent in English or Spanish
- Permanent atrial fibrillation
- Pregnancy (in prospective arm only)
- Expected survival <1 year
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Retrospective Impulse Dynamics Optimizer Device Patients with available data for 6 months before the implantation of the Optimizer implantation and at least 8 months after the implantation of the optimizer at the time the study is initiated and patients with available data for 6 months before the implantation of the Optimizer implantation, but less than 8 months of follow up after Optimizer implantation at the time of the study initiation. Prospective Impulse Dynamics Optimizer Device Patients prior to the implantation of the Optimizer that will take place as per standard of care.
- Primary Outcome Measures
Name Time Method Change in Atrial Fibrillation (AF) Burden 8 months post optimizer implantation Compare the AF burden noted 6 months pre Optimizer implant to 6 post Optimizer months (post Optimizer months 3-8), after 2 month blanking period
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Hackensack Univeristy Medical Center
🇺🇸Hackensack, New Jersey, United States